Danaher (NYSE:DHR) Releases Q3 Earnings Guidance

Danaher (NYSE:DHR) issued an update on its third quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.12-1.15 for the period, compared to the Thomson Reuters consensus estimate of $1.16. Danaher also updated its FY 2019 guidance to $4.75-4.80 EPS.

Shares of Danaher stock traded down $1.39 during trading hours on Friday, reaching $141.61. The company had a trading volume of 3,821,795 shares, compared to its average volume of 2,343,584. Danaher has a one year low of $94.59 and a one year high of $145.50. The business has a fifty day moving average price of $140.27. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.74 and a current ratio of 2.18. The company has a market cap of $102.38 billion, a price-to-earnings ratio of 31.33, a PEG ratio of 2.58 and a beta of 0.96.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Thursday, July 18th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.15 by $0.04. The company had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. Danaher had a return on equity of 11.73% and a net margin of 12.22%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the company earned $1.15 earnings per share. As a group, equities research analysts predict that Danaher will post 4.78 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend is Thursday, June 27th. Danaher’s dividend payout ratio is 15.04%.

Several research firms recently issued reports on DHR. Piper Jaffray Companies raised Post from a neutral rating to an overweight rating and lifted their price objective for the company from $106.00 to $130.00 in a research note on Thursday. Zacks Investment Research lowered GALP ENERGIA SG/ADR from a hold rating to a sell rating in a research note on Monday, May 6th. Robert W. Baird lifted their price objective on Danaher from $131.00 to $148.00 and gave the company an outperform rating in a research note on Friday. Janney Montgomery Scott lifted their price objective on Danaher from $136.00 to $174.00 and gave the company a buy rating in a research note on Wednesday, April 17th. Finally, Needham & Company LLC reissued a buy rating and set a $155.00 price objective (up previously from $142.00) on shares of Danaher in a research note on Friday. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $139.08.

In other Danaher news, CFO Matthew Mcgrew sold 22,738 shares of Danaher stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $130.89, for a total transaction of $2,976,176.82. Following the completion of the sale, the chief financial officer now owns 27,534 shares of the company’s stock, valued at $3,603,925.26. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Alan G. Spoon sold 1,913 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $129.52, for a total value of $247,771.76. Following the sale, the director now directly owns 86,863 shares of the company’s stock, valued at approximately $11,250,495.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 453,448 shares of company stock valued at $59,724,640. Corporate insiders own 11.40% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Read More: Book Value Per Share – BVPS

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.